Skip to main content

Articles

FDA Approvals, Lung Cancer, Oncology

Opdivo plus Yervoy and Limited Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression

FDA Approvals, Lung Cancer, Oncology

Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma

ASCO 2020 - Lung Cancer

Impact of Immune-Related Adverse Events on Checkpoint Inhibitor Consolidation Therapy in Stage III NSCLC

ASCO 2020 - Lung Cancer

Characteristics of Patients Who Achieve Long-Term Response with PD-1 Blockade

ASCO 2020 - Lung Cancer

Smoking Cessation and Lung Cancer: Recent Quitters Benefit Too

ASCO 2020 - Lung Cancer

Weekly Epirubicin as Second-Line Therapy for Malignant Pleural Mesothelioma

ASCO 2020 - Lung Cancer

Patterns of Acquired Resistance in Patients with NSCLC Who Receive PD-1 Inhibitors

ASCO 2020 - Lung Cancer

ADAURA Results: Osimertinib as Adjuvant Therapy for EGFR-Mutated NSCLC

ASCO 2020 - Lung Cancer

Cediranib Combined with Olaparib Is Active in Patients with Platinum-Pretreated SCLC

ASCO 2020 - Lung Cancer

Nationwide Genomic Screening Network Can Be Effective in Identifying Rare Targetable Genetic Alterations

Page 35 of 244
Results 341 - 350 of 2436